🇺🇸 FDA
Pipeline program

TAK-881

TAK-881-3002

Phase 3 mab active

Quick answer

TAK-881 for Primary Immunodeficiency Diseases (PID) is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Primary Immunodeficiency Diseases (PID)
Phase
Phase 3
Modality
mab
Status
active

Clinical trials